❌

Reading view

Biomarkers, omics and artificial intelligence for early detection of pancreatic cancer

Semin Cancer Biol. 2025 Jun;111:76-88. doi: 10.1016/j.semcancer.2025.02.009. Epub 2025 Feb 20.

ABSTRACT

Pancreatic ductal adenocarcinoma (PDAC) is frequently diagnosed in its late stages when treatment options are limited. Unlike other common cancers, there are no population-wide screening programmes for PDAC. Thus, early disease detection, although urgently needed, remains elusive. Individuals in certain high-risk groups are, however, offered screening or surveillance. Here we explore advances in understanding high-risk groups for PDAC and efforts to implement biomarker-driven detection of PDAC in these groups. We review current approaches to early detection biomarker development and the use of artificial intelligence as applied to electronic health records (EHRs) and social media. Finally, we address the cost-effectiveness of applying biomarker strategies for early detection of PDAC.

PMID:39986585 | DOI:10.1016/j.semcancer.2025.02.009

  •  

Systems-level design principles of metabolic rewiring in an animal

Nature, Published online: 26 February 2025; doi:10.1038/s41586-025-08636-5

Systems-level Worm Perturb-Seq of metabolic genes reveals design principles of transcriptional metabolic rewiring, many of which can be explained by a compensation–repression model.
  •  

Rare disease gene association discovery in the 100,000 Genomes Project

Nature, Published online: 26 February 2025; doi:10.1038/s41586-025-08623-w

A rare variant burden analytical framework for Mendelian diseases was developed and applied to data from the 100,000 Genomes Project, identifying 69 probable new disease–gene associations.
  •  

Technology shapes relationships. Relationships shape technology.

Greetings from a cold winter day.

As I write this letter, we are in the early stages of President Donald Trump’s second term. The inauguration was exactly one week ago, and already an image from that day has become an indelible symbol of presidential power: a photo of the tech industry’s great data barons seated front and center at the swearing-in ceremony.

Elon Musk, Sundar Pichai, Jeff Bezos, and Mark Zuckerberg all sat shoulder to shoulder, almost as if on display, in front of some of the most important figures of the new administration. They were not the only tech leaders in Washington, DC, that week. Tim Cook, Sam Altman, and TikTok CEO Shou Zi Chew also put in appearances during the president’s first days back in action. 

These are tycoons who lead trillion-dollar companies, set the direction of entire industries, and shape the lives of billions of people all over the world. They are among the richest and most powerful people who have ever lived. And yet, just like you and me, they need relationships to get things done. In this case, with President Trump. 

Those tech barons showed up because they need relationships more than personal status, more than access to capital, and sometimes even more than ideas. Some of those same people—most notably Zuckerberg—had to make profound breaks with their own pasts in order to forge or preserve a relationship with the incoming president. 

Relationships are the stories of people and systems working together. Sometimes by choice. Sometimes for practicality. Sometimes by force. Too often, for purely transactional reasons. 

That’s why we’re exploring relationships in this issue. Relationships connect us to one another, but also to the machines, platforms, technologies, and systems that mediate modern life. They’re behind the partnerships that make breakthroughs possible, the networks that help ideas spread, and the bonds that build trust—or at least access. In this issue, you’ll find stories about the relationships we forge with each other, with our past, with our children (or not-quite-children, as the case may be), and with technology itself. 

Rhiannon Williams explores the relationships people have formed with AI chatbots. Some of these are purely professional, others more complicated. This kind of relationship may be novel now, but it’s something we will all take for granted in just a few years. 

Also in this issue, Antonio Regalado delves into our relationship with the ecological past and the way ancient DNA is being used not only to learn new truths about who we are and where we came from but also, potentially, to address modern challenges of climate and disease.

In an extremely thought-provoking piece, Jessica Hamzelou examines people’s relationships with the millions of IVF embryos in storage. Held in cryopreservation tanks around the world, these embryos wait in limbo, in ever growing numbers, as we attempt to answer complicated ethical and legal questions about their existence and preservation. 

Turning to the workplace, Rebecca Ackermann explores how our relationships with our employers are often mediated through monitoring systems. As she writes, what may be more important than the privacy implications is how the data they collect is “shifting the relationships between workers and managers” as algorithms “determine hiring and firing, promotion and ‘deactivation.’” Good luck with that.

Thank you for reading. As always, I value your feedback. So please, reach out and let me know what you think. I really don’t want this to be a transactional relationship. 

Warmly,

Mat Honan
Editor in Chief
mat.honan@technologyreview.com

  •  

Using prognostic signatures and machine learning to identify core features associated with response to CDK4/6 inhibitor-based therapy in metastatic breast cancer

Oncogene, Published online: 26 February 2025; doi:10.1038/s41388-025-03308-0

Using prognostic signatures and machine learning to identify core features associated with response to CDK4/6 inhibitor-based therapy in metastatic breast cancer
  •  

Imaging and outcome correlates of ctDNA methylation markers in prostate cancer: a comparative, cross-sectional [⁶⁸Ga]Ga-PSMA-11 PET/CT study

To validate the clinical utility of a previously identified circulating tumor DNA methylation marker (meth-ctDNA) panel for disease detection and survival outcomes, meth-ctDNA markers were compared to PSA leve...
  •  

Liquid Biopsy in early breast cancer Will minimal residual disease monitoring be part of routine surveillance?

Oncol Res Treat. 2025 Feb 25:1-11. doi: 10.1159/000544838. Online ahead of print.

ABSTRACT

BACKGROUND: Current breast cancer (BC) surveillance is limited to the detection of local, locoregional or contralateral recurrence. This is based on two outdated studies from the 1990s and ignores current evidence on liquid biopsies, particularly circulating tumor DNA (ctDNA).

SUMMARY: ctDNA has been shown to be a reliable prognostic biomarker in early BC surveillance. It can be detected using a tumor-informed or a tumor-agnostic approach. However, conclusive evidence for a survival benefit from ctDNA-guided follow-up, as needed for a paradigm shift in BC surveillance, is still lacking. According to current studies, the lead time, i.e. the time from biomarker detection to clinically overt relapse, can be up to several months. This stage of MRD (minimal or molecular residual disease) offers a new therapeutic window, and, currently, several studies are evaluating the efficacy of treatments initiated within this therapeutic window, based on a positive biomarker finding. Liquid biopsy might also open up the possibility of de-escalating therapy in patients with a negative biomarker result.

PMID:39999817 | DOI:10.1159/000544838

  •  

Tumor microenvironment and drug resistance in lung adenocarcinoma: molecular mechanisms, prognostic implications, and therapeutic strategies

Discov Oncol. 2025 Feb 25;16(1):238. doi: 10.1007/s12672-025-01981-x.

ABSTRACT

The fight against lung adenocarcinoma (LUAD) is challenged by tumor microenvironment (TME)-mediated drug resistance, which limits effective treatment. This study examines the LUAD TME and identifies four distinct subtypes through multi-omics profiling: immune-rich, immune-exhausted, stromal-dominant, and TME-desert. Each subtype has unique molecular features, tumor diversity, and links to clinical outcomes. Immune-rich subtypes respond better to immune checkpoint inhibitors, while stromal-dominant and TME-desert subtypes show resistance to treatment and poor prognosis. Molecular analysis uncovers subtype-specific mutations, chromosomal instability, and altered signaling pathways, pointing to potential therapeutic targets. In silico drug screening identifies promising treatments for resistant subtypes. These findings, validated in independent cohorts, highlight the critical role of the TME in drug resistance and treatment response, providing insights for personalized treatment strategies in LUAD.

PMID:40000527 | PMC:PMC11861463 | DOI:10.1007/s12672-025-01981-x

  •  
❌